The Role of Hormonal Dysregulation in Systemic Sclerosis

激素失调在系统性硬化症中的作用

• 批准号: 10685579
• 负责人: DeAnna Baker Frost
• 金额: $ 18.66万
• 依托单位: MEDICAL UNIVERSITY OF SOUTH CAROLINA
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-08-17 至 2027-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10685579
• 关键词: Advisory Committees; Affect; African American; African American population; Age; Aromatase Inhibitors; Autoantibodies; Autoimmune Diseases; Basic Science; Bioinformatics; Biological Markers; Biology; Caucasians; Cessation of life; Characteristics; Clinical; Clinical Research; Cost of Illness; Cutaneous; Data Analyses; Dehydroepiandrosterone Sulfate; Dermal; Diagnosis; Diffuse; Diffuse Scleroderma; Direct Costs; Disease; Disease Outcome; Estradiol; Estradiol Receptors; Estrogen Receptor alpha; Estrogen Receptors; Estrogens; Extracellular Matrix; FDA approved; Facilities and Administrative Costs; Female; Fibroblasts; Fibronectins; Fibrosis; Fostering; Foundations; Fulvestrant; Gender; Gene Expression; Gene Expression Profile; General Population; Genetic Transcription; Genomics; Goals; Gonadal Steroid Hormones; Hormonal; Human; In Vitro; Knock-out; Knockout Mice; Measures; Mediator; Mentors; Modeling; Morbidity - disease rate; Mus; Outcome; Pathogenesis; Patients; Pharmaceutical Preparations; Postmenopause; Production; Profibrotic signal; Prognosis; Protein Isoforms; Receptor Signaling; Research; Research Institute; Research Support; Resources; Rheumatology; Role; Serum; Severities; Severity of illness; Signal Transduction; Skin; Skin Tissue; South Carolina; Systemic Scleroderma; Testing; Testosterone; Time; Tissue-Specific Gene Expression; Training; Transforming Growth Factor Beta 2; Transforming Growth Factor beta; Translational Research; Woman; career; career development; clinical center; cohort; disability; ethnic diversity; experience; in vivo; innovation; mRNA sequencing; male; mortality; mouse model; negative affect; new therapeutic target; non-genomic; novel; personalized medicine; potential biomarker; prevent; sex; skin fibrosis; supportive environment; targeted treatment; time interval; transcriptomics

Although patients with systemic sclerosis (SSc) have increased disability, morbidity, and mortality, no current FDA-approved medications for SSc prevent or reverse fibrosis. Our long-term goal is to understand how E2 influences fibrosis in SSc, which provides the rationale for using medications that inhibit E2 production and signaling (aromatase inhibitors and fulvestrant, respectively) for SSc treatment. The overall objectives of this proposal are to identify the estrogen receptors (ERs) needed for E2-induced fibrosis, the transcriptomic alterations caused by E2 and ER signaling in human skin, and any associations between systemic E2 levels and disease outcomes. The central hypothesis is that hormonal dysregulation promotes dermal fibrosis through time- dependent signal propagation via ER(s), leading to increased pro-fibrotic gene transcription and worse SSc clinical outcomes. The rationale for this project is to understand how E2 leads to fibrosis by incorporating the cellular, transcriptomic and systemic effects of estradiol. We will test our hypothesis with the following specific aims: (1) Identify the contribution of ERs in E2-induced dermal fibrosis; (2) Determine the novel transcriptomic profile of E2-induced dermal fibrosis ex vivo; and (3) Determine associations between hormonal dysregulation and clinical outcomes in SSc. In the first aim, we will use 3 models to examine how ERs affect fibrosis: human and mouse primary dermal fibroblasts in vitro, ERα-null and GPER1 KO mice in vivo, and human skin tissue ex vivo. In the second aim, we will stimulate human skin with E2 at various time points to assess differential gene expression using mRNA seq and determine which ERs are responsible for these specific transcriptomic alterations. In the third aim, we will compare levels of the sex hormones E2, dehydroepiandrosterone sulfate and testosterone in African American and Caucasian patients with limited SSc and diffuse SSc as well as in healthy controls and estimate associations among hormonal level, autoantibody status, and clinical measures of disease severity. The project is innovative because understanding the role of ERs (ERα isoforms and GPER1) in fibrosis and discovering clinical associations between sex hormones and SSc raise the prospect of using systemic hormonal levels as a biomarker for SSc disease characteristics, severity and prognosis. The proposed research is significant because it provides the basis for using estrogen modulators to treat SSc. My long-term career goal is to understand the relationship between SSc-related fibrosis and estrogen using basic science and clinical research, with the hope of developing personalized medicine targets. To accomplish this goal, I will obtain training in receptor signaling biology, bioinformatic data interpretation and clinical research. MUSC contains resources such as the Core Center for Clinical Research and the CTSA-sponsored South Carolina Clinical & Translational Research Institute which provide necessary research support and career development. My mentor and co-mentor, advisory committee and the Division of Rheumatology all foster a supportive environment, allowing for successful completion of this proposal and continued progression toward independence.

尽管系统性硬化症（SSc）患者的残疾、发病率和死亡率增加，但目前没有研究表明， FDA批准的SSc药物可预防或逆转纤维化。我们的长期目标是了解E2 影响SSc的纤维化，这为使用抑制E2产生的药物提供了理论基础， 信号传导（分别为芳香酶抑制剂和氟维司群）用于SSc治疗。这一总体目标 我们的建议是确定雌激素受体（ER）所需的E2诱导的纤维化，转录组学 人类皮肤中E2和ER信号传导引起的改变，以及全身E2水平和 疾病结果。核心假设是激素失调会随着时间的推移促进真皮纤维化- 通过ER的依赖性信号传播，导致促纤维化基因转录增加和SSc恶化 临床结果。该项目的基本原理是了解E2是如何通过结合 雌二醇的细胞、转录组和全身效应。我们将用以下具体数据来检验我们的假设： 目的：（1）确定ER在E2诱导的真皮纤维化中的作用;（2）确定新的转录组学机制， 离体E2诱导的真皮纤维化的特征;和（3）确定激素失调之间的关联 和SSc的临床结果。在第一个目标中，我们将使用3种模型来研究ER如何影响纤维化：人类 和小鼠原代真皮成纤维细胞，ERα-null和GPER 1 KO小鼠体内，以及人皮肤组织， vivo.在第二个目标中，我们将在不同的时间点用E2刺激人类皮肤，以评估差异基因。 表达，并确定哪些ER负责这些特定的转录组学。 改变。在第三个目标中，我们将比较性激素E2、硫酸脱氢表雄酮和 非裔美国人和高加索人局限性SSc和弥漫性SSc患者以及健康 控制和估计激素水平、自身抗体状态和疾病临床指标之间的关联 严重性。该项目具有创新性，因为了解ERα亚型和GPER 1在纤维化中的作用 发现性激素和SSc之间的临床联系，提高了系统性治疗SSc的前景。 激素水平作为SSc疾病特征、严重程度和预后的生物标志物。拟议研究 是重要的，因为它提供了使用雌激素调节剂治疗SSc的基础。我的长期职业目标 是利用基础科学和临床研究来了解Ssc相关纤维化和雌激素之间的关系， 研究，希望开发个性化的药物靶点。为了实现这一目标，我将 受体信号生物学、生物信息学数据解释和临床研究方面的培训。MUSC包含 资源，如临床研究核心中心和CTSA赞助的南卡罗来纳州临床和 翻译研究所提供必要的研究支持和职业发展。我的导师 和共同导师，咨询委员会和流变学部门都促进了一个支持性的环境， 从而使这项提案得以顺利完成，并继续朝着独立的方向前进。